Wang Xin, Wang Lei, Wang Huayong, Zhang Hao
Department of Thoracic Surgery, Xuzhou Central Hospital, Xuzhou, China.
Cell Biochem Biophys. 2015 Jun;72(2):471-3. doi: 10.1007/s12013-014-0489-0.
The objective of this study is to compare the effectiveness of olanzapine combined with ondansetron or ondansetron alone in preventing chemotherapy-induced nausea and vomiting (CINV) of non-small cell lung cancer (NSCLC). A total of 84 NSCLC patients were equally randomized into intervention group and control group. Both groups were intravenously administered with ondansetron 8 mg 30 min before chemotherapy. In the intervention group, olanzapin 10 mg was orally administered for 8 days, beginning from the first morning of chemotherapy. The antiemetic effectiveness was evaluated in the first chemotherapy cycle. The incidence of acute vomiting was 33.33 % (14/42) and 54.76 % (23/42) in the intervention group and control group (p < 0.05) whereas that of delayed vomiting was 16.57 % (7/42) and 47.62 % (20/42) (p < 0.05). Compared with ondansetron alone, the combination of olanzapine with ondansetron has better effectiveness in preventing CINV in NSCLC patients, particularly for the delayed type.
本研究的目的是比较奥氮平联合昂丹司琼或单用昂丹司琼预防非小细胞肺癌（NSCLC）化疗引起的恶心和呕吐（CINV）的有效性。总共84例NSCLC患者被平均随机分为干预组和对照组。两组在化疗前30分钟均静脉注射8毫克昂丹司琼。在干预组中，从化疗的第一个早晨开始，口服10毫克奥氮平，持续8天。在第一个化疗周期中评估止吐效果。干预组和对照组的急性呕吐发生率分别为33.33%（14/42）和54.76%（23/42）（p<0.05），而延迟性呕吐的发生率分别为16.57%（7/42）和47.62%（20/42）（p<0.05）。与单用昂丹司琼相比，奥氮平联合昂丹司琼在预防NSCLC患者CINV方面具有更好的效果，尤其是对延迟性类型。
